Skip to main content
MANNKIND CORP logo

MANNKIND CORP — Investor Relations & Filings

Ticker · MNKD ISIN · US56400P7069 LEI · 213800GFBCNY1ZFST722 US Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2014-01-04 Director's Dealing
Country US United States of America
Listing US MNKD

About MANNKIND CORP

https://mannkindcorp.com/

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products and devices. The company specializes in inhaled therapies for patients with cardiometabolic and orphan lung diseases. Its portfolio includes Afrezza®, an inhaled insulin for diabetes, and Tyvaso DPI®, a dry powder inhaler for pulmonary hypertension developed in collaboration with United Therapeutics. Through its acquisition of scPharmaceuticals, MannKind also markets FUROSCIX®, a subcutaneous treatment for edema in adults with chronic heart failure. The company's pipeline is focused on expanding indications for its existing products, including a pediatric application for Afrezza.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2014-01-04 English
FORM 4 SUBMISSION
Director's Dealing
2013-12-24 English
POSASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, dated December 23, 2013, for MannKind Corporation. It is a prospectus related to the registration of shares issuable upon conversion of senior secured convertible notes. The document discusses the offering, use of proceeds, selling stockholders, and related legal and risk factors. It is a detailed registration statement for securities offering, not a financial report, earnings release, or management discussion. The document is primarily about capital raising and securities registration under the Securities Act of 1933. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not RPA or RNS.
2013-12-23 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content details the creation of a direct financial obligation through a Facility Agreement involving convertible notes and related transactions. It includes specific dates, transaction details, and forward-looking statements. There are no comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a certification or a brief announcement but a detailed regulatory filing about financing activities. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2013-12-13 English
FORM 4 SUBMISSION
Director's Dealing
2013-12-13 English
FORM 4 SUBMISSION
Director's Dealing
2013-12-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.